305 results about "Pregabalin" patented technology

The present invention relates to stable once daily sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable excipient wherein pharmaceutical composition is bioequivalent to conventional immediate release formulation of pregabalin administered twice daily. The present invention further relates to a composition comprising pregabalin and sugar esters as release retarding agent for maintaining uniform release rate of the drug and process for the preparation of such oral sustained release formulations.

Methods of treating or preventing chronic pain or convulsion are disclosed by administering to an animal a sodium channel blocker and at least one of gabapentin and pregabalin. Also disclosed are pharmaceutical compositions and kits for the treatment or prevention of chronic pain or convulsion.

This invention provides a method of making (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid (pregabalin) or a salt thereof via an asymmetric hydrogenation synthesis. Pregabalin is useful for the treatment and prevention of seizure disorders, pain, and psychotic disorders. The invention also provides intermediates useful in the production of pregabalin.

A method is provided for using α₂δ subunit calcium channel modulators or other compounds that interact with the α₂δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat pain. According to the present invention, α₂δ subunit calcium channel modulators include GABA analogs (e.g., gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.

The invention encompasses the synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid, (S)-Pregabalin, via the intermediate, (3R)-5-methyl-3-(2-oxo-2{[(1R)-1-phenylethyl]amino}ethyl)hexanoic acid.

A method is provided for using α₂δ subunit calcium channel modulators or other compounds that interact with the α₂δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, α₂δ subunit calcium channel modulators include GABA analogs, e.g., gabapentin and pregabalin, fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

The invention relates to a novel crystalline form of pregabalin drug for treating epilepsy and neuropathic pain and its preparation method. Compared to others pregabalin with agraphitic form and other forms, pregabalin with the novel crystalline form has good stability and is suitable for mass production. Pregabalin with the novel crystalline form uses Cu-Ka radiation and its X-ray powder diffraction has characteristic peak at 9.5(9.3), 12.3(7.2), 16.7(5.3), 18.4(4.8), 19.9(4.5) and 23.3(3.8) with the coordinate of 2-theta and interplanar spacing (d).

The invention discloses a synthetic method of pregabalin. According to the synthetic method, isovaleraldehyde and cyanoacetic alkyl ester are used as starting materials; condensation reaction, Michael addition reaction, hydrolysis reaction, amidation reaction and the like are carried out successively to obtain 3-(carbamoyl methyl)-5-methyl-hexanoic acid; and resolution and Hofmann elimination are carried out to obtain pregabalin. The greatest improvement of the synthetic method is to carry out the hydrolysis reaction and the amidation reaction under the condition of near-critical water. Thus, addition of a catalyst is avoided, and yield of the reaction is raised. In addition, a flow reactor can be applied to the reaction so as to obtain a better reaction effect.

The invention discloses nitrilase from brassica rapa, encoding genes and an application of the encoding genes to the preparation of pregabalin chiral intermediate (S)-3-cyan-5-methylhexanoic acid through biocatalysis, and an amino acid sequence of the nitrilase is shown as SEQ ID NO:1. The invention provides novel nitrilase for preparing the (S)-3-cyan-5-methylhexanoic acid with high region and high stereoselectivity through hydrolysis, the concentration of hydrolysis substrates of the nitrilase can reach more than 1 M, and an ee (enantiomeric excess) value is kept more than 99 percent. The pregabalin important chiral intermediate (S)-3-cyan-5-methylhexanoic acid can be prepared through the nitrilase; a preparation method of the (S)-3-cyan-5-methylhexanoic acid has the advantages of high atom economy, mild conditions, environmental friendliness and the like and has high industrial application potential.

The invention relates to a pregabalin controlled release preparation, and a preparation method thereof. The pregabalin controlled release preparation comprises following ingredients, by weight, 30 to 75% of pregabalin, 5 to 40% of a filling material, 5 to 30% of a sustained-release material, 1 to 10% of an adhesive, and the balance an auxiliary material. The auxiliary material is one or more selected from magnesium stearate, talc, superfine silica powder, cetanol, octadecanol, liquid paraffin, stearic acid, sodium bicarbonate, magnesium carbonate and calcium carbonate; the sustained-release material is one or a mixture of more selected from ethyl cellulose, carbomer, polycarbophil, alginate, hydroxypropyl methyl cellulose, polyacrylic resin, and carnauba wax. The pregabalin controlled release preparation is capable of prolonging residence time of medicine in stomach, releasing long-lasting release and absorption of medicine, and further increasing bioavailability of medicine.

The present invention relates to a pharmaceutical composition useful for preventing/treating pain, which comprises combination of gabapentin or pregabalin, or pharmaceutically acceptable salts thereof and N-type calcium channel antagonists or pharmaceutically acceptable salts thereof such as a compound having the following structure.

The invention belongs to the field of medicinal preparations, and particularly relates to a pregabalin slow release medicine composition. The pregabalin slow release medicine composition comprises active ingredients and excipients, wherein the active ingredients are pregabalin or pharmaceutically acceptable salts of the pregabalin; the excipients comprise a matrix forming agent and a swelling agent; the matrix forming agent is a mixture of polyvinyl acetate and polyvinylpyrrolidone; the swelling agent is selected from one or any combination from croscarmellose sodium, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose and polyoxyethylene. The medicine composition is suitable for oral administration once in each day; the number of medication times is reduced; the blood concentration peak-to-valley ratio is reduced; meanwhile, the proper swelling agent is selected, so that the gastric retention can be reached, and the problem of stability caused by peroxides can also be avoided; the product stability is improved; the therapy effect can be achieved through once medication in each day; the effect of the medicine composition is equivalent to that of quick release preparations. The medicine composition is manly used for treating epilepsy, neuropathic pain and the like.

The invention belongs to analytical chemistry region, and relates to the method of measuring chiral isomer of by high efficiency liquid chromatography after pregabalin deriving. The method of precolumn derivation supplied by the invention has advantages of geniality reaction conditions, steady derivation offspring, fast reaction rate, little subsidiary reaction, etc. It could realize separation and measuration for pregabalin and chiral isomer containing pregabalin preparation.

A method is provided for treatment of non-painful bladder disorders, particularly non-painful overactive bladder without loss of urine. The method comprises administration of an α₂δ subunit calcium channel modulator, including gabapentin, pregabalin, GABA analogs, fused bicyclic or tricyclic amino acid analogs of gabapentin, amino acid compounds, and other compounds that interact with the α₂δ calcium channel subunit.

The invention relates to a medicinal composition with pregabalin as the active constituent, its preparing process and use, which comprises pregabalin as the medicinal active constituent, as well as pharmaceutically acceptable auxiliary materials, The composition can be used for treating peripheral nerve pain and epilepsy, and can be prepared into the forms of tablets, capsules, dispersible tablets, granules, soft capsules, chewable tablets, buccal tablets, buccal tablets or other oral preparations.

The invention discloses a pregabalin stomach floating-type slow-release tablet. The pregabalin stomach floating-type slow-release tablet comprises an active ingredient, a framework material, a swelling agent and an excipient. The active ingredient is pregabalin and pharmacologically acceptable salt, a solvate, a hydrate or a complex thereof. The framework material is combination of any one or moreof hydroxypropyl methylcellulose, hydroxypropylcellulose, acrylic resin and derivatives thereof, wherein the active ingredient accounts for 7-33% of a total weight of the slow-release tablet, the framework material accounts for 5-50% of the total weight of the slow-release tablet, the swelling agent accounts for 5-55% of the total weight of the slow-release tablet, and the balance of the excipient. The pregabalin stomach floating-type slow-release tablet is capable of, through selecting the suitable combination of the framework material and the swelling agent, achieving the following purposes: 1) prolonging residence time of the slow-release tablet in a stomach, enabling a drug to be continuously released and absorbed, and reducing fluctuation of blood concentration; and 2) reducing the physiological condition effect of a patient, and enabling the efficacy of the slow-release tablet to have a smaller individual difference.

The invention belongs to technical field of medicine, and particularly relates to a pregabalin orally disintegrating tablet and a dispersible tablet and the preparation method thereof. A prescription of the pregabalin orally disintegrating tablet and dispersible tablet contains at least one disintegrating agent and insoluble auxiliary material at a certain ratio, so that the disintegration time of six pregabalin orally disintegrating tablets is less than three minutes in one hundred ml of water at the temperature of 2o DEG C, while the disintegration time of pregabalin dispersible table is less than 30 seconds in 2 ml of water at the temperature of 24 DEG C. The bulk pharmaceutical chemicals of pregabalin orally disintegrating tablet and dispersible tablet are controlled in smaller grain size (74 to 250 microns). Combined with the technology of wet granulation, the problem of poor compressibility of pregabalin powder is solved. The solubility of pregabalin orally disintegrating tablet and dispersible tablet can reach more than 85 percent within 15 minutes in different PH mediums.

The present invention is directed to a regio- and stereoselective bioconversion of selected aliphatic dinitriles into corresponding cyanocarboxylic acids. More particularly, the present invention provides methods for the conversion of 2-isobutyl-succinonitrile into (S)-3 cyano-5-methylhexanoic acid, which is a useful intermediate in the synthesis of (S)-3(aminomethyl)-5-methylhexanoic acid (pregabalin). Pregabalin can be used for treating certain cerebral diseases, for example, in the treatment and prevention of seizure disorders, pain, and psychotic disorders.

The present invention provides an improved process for the preparation of a compound of formula (I), which comprises the steps of: formula (I), (a) reacting isovaleraldehyde of formula (II) and alkyl cyanoacetate of formula (III) optionally in presence of salts of weak acid and weak base or weak base in a suitable solvent to get 2-cyano-5-methyl-hex-2-enoic acid alkyl ester of formula (IV); (b) reacting 2-cyano-5-methyl-hex-2-enoic acid alkyl ester of formula (IV) with a suitable cyanide source in water or in an organic solvent or mixture thereof to get 2-isobutylsuccinonitrile of formula (V); (c) obtaining optionally 2-isobutylsuccinonitrile of formula (V) by reacting isovaleraldehyde of formula (II) and alkyl cyanoacetate of formula (III) in presence of suitable cyanide source in water or in an organic solvent or mixture thereof in single step; (d) converting 2-isobutylsuccinonitrile of formula pa (V) to racemic 3-cyano-5-methyl-hexanoic acid or salt thereof of formula (VI) with a genetically modified nitrilase enzyme (Nit pt 9N_56_2) in water or optionally with an organic co-solvent at appropriate pH and temperature; (e) converting racemic 3-cyano-5-methyl-hexanoic acid or salt thereof of formula (VI) to racemic alkyl 3-cyano-5-methyl-hexanoate of formula (VII) by treatment with alcohol (R3OH) and acidic catalyst or alkyl halide (R3X) in presence of a base in a suitable solvent or a mixture of solvents thereof; (f) obtaining (S)-alkyl 3-cyano-5-methyl-hexanoate of formula (VIII) and (R)-3-cyano-5-methyl-hexanoic acid or salt thereof of formula (X) by enzymatic enantioselective hydrolysis in water or organic solvent or a mixture thereof from racemic alkyl 3-cyano-5-methyl-hexanoate of formula (VII); (g) obtaining optionally the compound of formula (VII) by racemizing unwanted (R)-3-cyano-5-methyl-hexanoic acid or salt thereof of formula (X) or substantially enriched (R)-3-cyano-5-methyl-hexanoic acid salt thereof of formula (X) in presence of a base in organic solvent or a mixture thereof; (h) converting (S)-alkyl 3-cyano-5-methyl-hexanoate of formula (VIII) to pregabalin of formula (I) by hydrolyzing ester group with suitable alkali or alkaline earth metal base followed by hydrogenation optionally in one pot in a solvent selected from water or other organic solvents or a mixture thereof in presence of a suitable hydrogenation catalyst.